Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allakos Inc. stock logo
ALLK
Allakos
$0.33
$0.33
$0.22
$1.56
$29.74M0.151.20 million shsN/A
Evotec SE stock logo
EVTCY
Evotec
$4.20
-3.2%
$4.13
$14.22
$26.57
$1.39B0.982,407 shs61,993 shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$20.96
$22.66
$16.60
$28.47
$1.55B1.58914,852 shs348,387 shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$37.20
+2.5%
$36.77
$16.65
$46.48
$5.83B1.912.92 million shs681,323 shs
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$76.01
$75.83
$23.77
$82.20
$3.81B-0.181.14 million shs4,322 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allakos Inc. stock logo
ALLK
Allakos
0.00%0.00%0.00%+4.48%-56.70%
Evotec SE stock logo
EVTCY
Evotec
0.00%+0.96%+2.44%+37.25%-15.15%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
0.00%+1.70%-12.08%+16.25%+4.28%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
0.00%+1.31%-5.34%-0.40%+97.98%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allakos Inc. stock logo
ALLK
Allakos
2.8748 of 5 stars
3.10.00.04.70.02.51.3
Evotec SE stock logo
EVTCY
Evotec
N/AN/AN/AN/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.7933 of 5 stars
3.42.00.00.02.92.50.6
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
3.2988 of 5 stars
1.41.00.03.52.72.51.9
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allakos Inc. stock logo
ALLK
Allakos
2.25
Hold$2.00507.72% Upside
Evotec SE stock logo
EVTCY
Evotec
0.00
N/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.75
Moderate Buy$33.2558.64% Upside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.80
Moderate Buy$40.809.68% Upside
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TGTX, EVTCY, SDGR, ALLK, and TPTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$28.00
4/16/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allakos Inc. stock logo
ALLK
Allakos
N/AN/AN/AN/A$1.93 per shareN/A
Evotec SE stock logo
EVTCY
Evotec
$572.16M2.42$0.04 per share105.53$2.52 per share1.67
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$230.49M6.67N/AN/A$5.78 per share3.63
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$386.39M15.28$0.12 per share306.10$1.43 per share26.01
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$30.83M123.46N/AN/A$15.84 per share4.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allakos Inc. stock logo
ALLK
Allakos
-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)
Evotec SE stock logo
EVTCY
Evotec
$7.14M$0.4110.24N/A20.85%16.02%7.81%N/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$23.38M$0.24155.0037.20N/A10.13%18.88%7.05%8/5/2025 (Estimated)
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/A

Latest TGTX, EVTCY, SDGR, ALLK, and TPTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.83N/AN/AN/A$52.03 millionN/A
5/7/2025Q1 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million
5/7/2025Q1 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.19$0.03-$0.16$0.03$117.07 million$120.86 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allakos Inc. stock logo
ALLK
Allakos
N/AN/AN/AN/AN/A
Evotec SE stock logo
EVTCY
Evotec
N/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allakos Inc. stock logo
ALLK
Allakos
N/A
6.08
6.08
Evotec SE stock logo
EVTCY
Evotec
0.53
2.57
2.50
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
3.45
3.45
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.03
4.02
3.04
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/A
16.83
16.83

Institutional Ownership

CompanyInstitutional Ownership
Allakos Inc. stock logo
ALLK
Allakos
84.64%
Evotec SE stock logo
EVTCY
Evotec
N/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
90.33%

Insider Ownership

CompanyInsider Ownership
Allakos Inc. stock logo
ALLK
Allakos
16.12%
Evotec SE stock logo
EVTCY
Evotec
N/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
8.60%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
10.64%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allakos Inc. stock logo
ALLK
Allakos
19090.38 million74.94 millionOptionable
Evotec SE stock logo
EVTCY
Evotec
4,200330.22 millionN/ANot Optionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79073.38 million67.07 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290158.76 million141.86 millionOptionable
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
25050.07 million45.77 millionNot Optionable

Recent News About These Companies

Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance
Glass System in Turning Point Residence
Turning Point Brands Inc.
Alzheimer’s: A Turning Point?
Turning Point Brands Inc (TPB)
Cormorant Asset Management, LP's Net Worth
Solving quadratic equations - Edexcel
BMS bet looking good as Augtyro approved in ROS1-positive NSCLC
A Turning Point for Japan-US Climate Cooperation?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allakos stock logo

Allakos NASDAQ:ALLK

$0.33 0.00 (0.00%)
As of 05/15/2025

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Evotec stock logo

Evotec OTCMKTS:EVTCY

$4.20 -0.14 (-3.23%)
As of 07/3/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$20.96 0.00 (0.00%)
Closing price 07/3/2025 03:29 PM Eastern
Extended Trading
$21.04 +0.08 (+0.38%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$37.20 +0.91 (+2.51%)
Closing price 07/3/2025 03:25 PM Eastern
Extended Trading
$36.94 -0.26 (-0.69%)
As of 07/3/2025 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Turning Point Therapeutics stock logo

Turning Point Therapeutics NASDAQ:TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.